Monument Therapeutics Advances Schizophrenia Treatment with £850k Funding

Monument Therapeutics, a pioneering neuroscience firm, has successfully secured £850k in funding to forward the development of its innovative treatment for cognitive impairment associated with schizophrenia (CIAS). The funding round was led by ACF Investors, alongside Wren Capital, o2h Ventures, and various angel investors, and it will underpin the company's efforts to progress its novel drug, MT1988, through clinical phases. Addressing a significant unmet medical need, MT1988 leverages a fixed-dose combination of small molecules that target nicotinic receptors, enhancing cognitive functions with minimized side effects. The investment signifies a substantial step in Monument's mission to utilize digital biomarkers in precision psychiatry, offering a transformative solution for patients whose cognitive symptoms have remained largely unaddressed until now. Proponents like Tim Mills from ACF Investors and Sunil Shah from o2h Ventures express strong support, recognizing the drug's potential to significantly impact the treatment landscape for schizophrenia and related cognitive impairments.